Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Whitehawk Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Whitehawk Therapeutics, Inc.

AADI WHWK

Whitehawk Therapeutics, Inc.

About Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. is an oncology-focused biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that target validated tumor antigens in solid and difficult-to-treat cancers. Leveraging advanced linker-payload technology and proprietary antibodies, Whitehawk aims to improve efficacy and safety by delivering potent Topoisomerase I inhibitor payloads directly to cancer cells. The company operates a virtual model, outsourcing clinical development and manufacturing, targeting global markets with high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Whitehawk Therapeutics, Inc.

1
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports No Revenue and $22.2 Million Net Loss for Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports $20.6M Net Loss and Strategic Shift Following FYARRO Divestiture

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports No Revenue in Q3 2025 Following FYARRO Divestiture

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports No Revenue and Increased Operating Expenses in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports 33.4% Revenue Growth and $73M Net Income in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Whitehawk Therapeutics, Inc. Whitehawk Therapeutics Reports $63.7M Net Loss for 2024, Increases Revenue from FYARRO

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Whitehawk Therapeutics, Inc. Aadi Bioscience Reports Q3 2024 Financial Results, Product Sales Growth, and Reduced Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments